Literature DB >> 28559023

The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement.

Ling-Long Tang1, Xin-Ran Tang1, Wen-Fei Li1, Lei Chen1, Li Tian2, Ai-Hua Lin3, Ying Sun1, Jun Ma4.   

Abstract

OBJECTIVES: To investigate the feasibility of contralateral lower neck sparing intensity modulation radiated therapy (IMRT) for nasopharyngeal carcinoma patients (NPC) with unilateral cervical lymph node metastasis.
MATERIALS AND METHODS: Retrospective review of 546 patients with unilateral cervical lymph node metastasis treated between November 2009 and February 2012 at one institution. All patients were staged using magnetic resonance imaging and received radical IMRT. Patients were classified into two groups: the inferior border of the negative neck irradiation field only covered Levels III to Va in Group 1; the inferior border covered entire neck down to Levels IV to Vb in Group 2.
RESULTS: Median follow-up was 49.9months (range, 1.3-69.2months). Four-year overall survival (OS:89.3% vs. 88.9%, P=0.91), disease-free survival (DFS:81.7% vs. 81.0%, P=0.91), distant metastasis-free survival (DMFS:88.2% vs. 87.9%, P=0.95), local relapse-free survival (LRFS:96.7% vs. 94.7%, P=0.70) and nodal relapse-free survival (NRFS: 96.1% vs. 95.9%, P=0.94) were not significantly different between Group 1 and Group 2. Twenty-two patients developed cervical lymph node relapse; of whom 20/22 (91.0%) developed unilateral relapse within pretreatment positive neck. Only one patient developed out-of-field relapse, though this patient also relapsed within the neck irradiation field (Level II). No clinicopathological feature tested had significant prognostic value for NRFS in multivariate analysis.
CONCLUSIONS: In the IMRT and MRI era, contralateral lower neck sparing IMRT seems to be feasible for NPC patients with unilateral cervical lymph node metastasis.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Elective neck prophylactic irradiation; Head and neck cancer; Intensity modulation radiated therapy; Magnetic resonance imaging; Nasopharyngeal carcinoma; Treatment outcome; Unilateral cervical lymph node metastasis

Mesh:

Year:  2017        PMID: 28559023     DOI: 10.1016/j.oraloncology.2017.03.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  5 in total

1.  Using ultrasound radiomics analysis to diagnose cervical lymph node metastasis in patients with nasopharyngeal carcinoma.

Authors:  Min Lin; Xiaofeng Tang; Lan Cao; Ying Liao; Yafang Zhang; Jianhua Zhou
Journal:  Eur Radiol       Date:  2022-09-07       Impact factor: 7.034

2.  Retrospective analysis of adjuvant radiotherapy in oral cavity or oropharyngeal cancer: Feasibility of omitting lower-neck irradiation.

Authors:  Sheng-Yow Ho; Wan-Chen Kao; Sheng-Yen Hsiao; Sheng-Fu Chiu; Sung-Wei Lee; Jia-Chun Chen; Li-Tsun Shieh
Journal:  PLoS One       Date:  2022-04-11       Impact factor: 3.240

3.  The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis.

Authors:  Jae Sik Kim; Bhumsuk Keam; Dae Seog Heo; Doo Hee Han; Chae-Seo Rhee; Ji-Hoon Kim; Kyeong Cheon Jung; Hong-Gyun Wu
Journal:  Cancer Res Treat       Date:  2019-01-29       Impact factor: 4.679

4.  Feasibility of ipsilateral lower neck sparing irradiation for unilateral or bilateral neck node-negative nasopharyngeal carcinoma: systemic review and meta-analysis of 2, 521 patients.

Authors:  Cheng-Long Huang; Cheng Xu; Yuan Zhang; Guan-Qun Zhou; Yan-Ping Mao; Qing Liu; Ying Sun; Jun Ma; Ling-Long Tang
Journal:  Radiat Oncol       Date:  2018-08-06       Impact factor: 3.481

5.  The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.

Authors:  Ling-Long Tang; Yu-Pei Chen; Chuan-Ben Chen; Ming-Yuan Chen; Nian-Yong Chen; Xiao-Zhong Chen; Xiao-Jing Du; Wen-Feng Fang; Mei Feng; Jin Gao; Fei Han; Xia He; Chao-Su Hu; De-Sheng Hu; Guang-Yuan Hu; Hao Jiang; Wei Jiang; Feng Jin; Jin-Yi Lang; Jin-Gao Li; Shao-Jun Lin; Xu Liu; Qiu-Fang Liu; Lin Ma; Hai-Qiang Mai; Ji-Yong Qin; Liang-Fang Shen; Ying Sun; Pei-Guo Wang; Ren-Sheng Wang; Ruo-Zheng Wang; Xiao-Shen Wang; Ying Wang; Hui Wu; Yun-Fei Xia; Shao-Wen Xiao; Kun-Yu Yang; Jun-Lin Yi; Xiao-Dong Zhu; Jun Ma
Journal:  Cancer Commun (Lond)       Date:  2021-10-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.